On Aug. 25, 2026, McKesson announced that it signed a definitive agreement to acquire Precision Medicine Group, a global provider of clinical research and biopharma commercialization services.

McKesson will acquire Precision Medicine Group for approximately $2.25 billion. Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment. The transaction is subject to customary closing conditions, including regulatory clearances. 

Precision Medicine Group supports next-generation approaches to drug development and commercialization. Life sciences innovators in biotechnology and pharmaceutical companies rely on Precision Medicine Group to move their discoveries from molecule to market with a breadth of integrated services and technology-enabled products, including biomarker intelligence, lab services, a global clinical research organization, market access consulting and commercialization support.